Abstract:
Objective: To explore the expression and prognostic significance of ADHs in hepatocellular carcinoma (HCC).Methods: The clinical data in this study were retrieved from The Cancer Genome Atlas (TCGA). The expression of ADHs was differentially analyzed in normal liver tissues and HCC by using the Metabolic gEne RApid Visualizer and the TCGA database, and the differentially expressed ADHs were selected for Kaplan‑Meier survival analysis. Cox analysis was performed to select factors that may influence the prognosis of HCC and to verify independent risk factors for HCC patients. The interaction among ADHs was explored at the gene level and protein expression level through GeneMAMIA and STRING, and the functional enrichment analysis of ADH family was carried out by using DAVID bioinformatics resources. Results: The expression levels of ADH1A, ADH1B, ADH1C, ADH4 and ADH7 in HCC were low. Patients with low expression level of ADH1A, ADH1B, ADH1C and ADH4 had poor survival rates, which may be related to the poor prognosis of HCC. Univariate Cox regression analysis showed that the expression levels of ADH1A, ADH1C and ADH4, as well as the clinical stage, T stage and M stage of the tumor were closely related to the overall survival rate of the patients. Multivariate Cox regression analysis further suggested that the low expression of ADH1A, ADH1C and ADH4 were independent risk factors affecting the prognosis of HCC patients. There was a pathway between ADH1A‑ADH1B, ADH1B‑ADH1C and ADH1A‑ADH1C, and ADHs were closely related to esterase D and aldehyde dehydrogenase. The ADHs were mainly involved in biological processes such as ethanol oxidation and retinol metabolism, and played a biological role in glycolysis/gluconeogenesis, chemical carcinogenesis and metabolism of xenobiotics by cytochrome P450. Conclusion: ADH1A, ADH1C and ADH4 may be biomarkers for the prognosis of HCC, providing reference value for the practical application of ADHs in HCC.